Peng Yuan

1.2k total citations
68 papers, 789 citations indexed

About

Peng Yuan is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peng Yuan has authored 68 papers receiving a total of 789 indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 27 papers in Cancer Research and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peng Yuan's work include Cancer Treatment and Pharmacology (29 papers), HER2/EGFR in Cancer Research (19 papers) and Breast Cancer Treatment Studies (18 papers). Peng Yuan is often cited by papers focused on Cancer Treatment and Pharmacology (29 papers), HER2/EGFR in Cancer Research (19 papers) and Breast Cancer Treatment Studies (18 papers). Peng Yuan collaborates with scholars based in China, United States and Australia. Peng Yuan's co-authors include Pin Zhang, Fei Ma, Ying Fan, Binghe Xu, Jiayu Wang, Yang Luo, Ruigang Cai, Qiao Li, Shanshan Chen and Qing Li and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Peng Yuan

62 papers receiving 776 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peng Yuan China	15	490	281	259	199	92	68	789
Davide Lombardi Italy	17	609 1.2×	308 1.1×	211 0.8×	210 1.1×	66 0.7×	57	1.0k
Olga Martínez‐Sáez Spain	11	458 0.9×	343 1.2×	298 1.2×	293 1.5×	95 1.0×	60	832
Federica Martorana Italy	14	375 0.8×	250 0.9×	226 0.9×	326 1.6×	70 0.8×	55	869
Teresa Di Desidero Italy	24	542 1.1×	253 0.9×	200 0.8×	421 2.1×	92 1.0×	52	1.1k
Eleanor Gutteridge United Kingdom	8	553 1.1×	268 1.0×	200 0.8×	214 1.1×	109 1.2×	27	800
Joyce Cheng United States	13	596 1.2×	370 1.3×	229 0.9×	244 1.2×	100 1.1×	31	943
Anna Fioravanti Italy	21	395 0.8×	192 0.7×	134 0.5×	326 1.6×	73 0.8×	38	896
Maria Rosa Cappelletti Italy	13	312 0.6×	251 0.9×	239 0.9×	213 1.1×	57 0.6×	32	635
Andrea Michelotti Italy	17	746 1.5×	240 0.9×	263 1.0×	187 0.9×	113 1.2×	60	1.3k
Rosemary Chester United Kingdom	6	366 0.7×	267 1.0×	155 0.6×	385 1.9×	42 0.5×	11	851

Countries citing papers authored by Peng Yuan

Since Specialization

Citations

This map shows the geographic impact of Peng Yuan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peng Yuan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peng Yuan more than expected).

Fields of papers citing papers by Peng Yuan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peng Yuan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peng Yuan. The network helps show where Peng Yuan may publish in the future.

Co-authorship network of co-authors of Peng Yuan

This figure shows the co-authorship network connecting the top 25 collaborators of Peng Yuan. A scholar is included among the top collaborators of Peng Yuan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peng Yuan. Peng Yuan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiang, Mingxia, Xue Yang, Mengqi Zhang, et al.. (2024). Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis. BMC Cancer. 24(1). 877–877. 2 indexed citations

Ma, Fei, Jiayu Wang, Pin Zhang, et al.. (2023). Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial. The Breast. 72. 103581–103581. 1 indexed citations

Xie, Yizhao, et al.. (2023). Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis. Frontiers in Endocrinology. 14. 1325540–1325540. 4 indexed citations

Yuan, Peng, Fei Ma, Ying Fan, et al.. (2023). Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node–Positive Breast Cancer. JAMA Network Open. 6(2). e230122–e230122. 6 indexed citations

Liu, Jiaxuan, Xin Wang, Yipeng Wang, et al.. (2023). Efficacy and safety of apatinib combined with dose‐dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis. International Journal of Cancer. 154(1). 133–144. 4 indexed citations

Huang, Li‐Ling, Xingsheng Hu, Yan Wang, et al.. (2021). Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients. Thoracic Cancer. 12(13). 1943–1951. 29 indexed citations

Li, Yiqun, Hongnan Mo, Xiuwen Guan, et al.. (2021). Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China. The Breast. 61. 129–135. 5 indexed citations

Chen, Xuelian, Ying Fan, Yang Luo, et al.. (2020). Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice. Clinical Breast Cancer. 21(3). 191–198. 5 indexed citations

Yue, Jian, et al.. (2020). 43P PDL1 protein expression is a prognostic factor in triple negative breast cancer. Annals of Oncology. 31. S30–S31.

10.

Li, Yiqun, Hongnan Mo, Xiuwen Guan, et al.. (2020). Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China. The Breast. 55. 30–36. 10 indexed citations

11.

Si, Yiran, Peng Yuan, Xue Wang, et al.. (2020). Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life. Annals of Surgical Oncology. 27(4). 1025–1033. 14 indexed citations

12.

Li, Qiao, Xiuwen Guan, Shanshan Chen, et al.. (2019). Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. Clinical Cancer Research. 25(17). 5212–5220. 61 indexed citations

13.

Mu, Yuxin, Pin Zhang, Fei Ma, et al.. (2018). [Clinical outcome of receptor expression discordance between primary and metastatic breast cancer].. PubMed. 40(7). 506–511. 1 indexed citations

14.

Lan, Bo, Fei Ma, Shanshan Chen, et al.. (2018). Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China. International Journal of Cancer. 143(10). 2499–2504. 16 indexed citations

15.

Lan, Bo, Fei Ma, Xiaoyu Zhai, et al.. (2018). The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. International Journal of Cancer. 143(1). 184–189. 27 indexed citations

16.

Lan, Bo, Fei Ma, Shanshan Chen, et al.. (2018). The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China. Clinical Breast Cancer. 19(2). e370–e375. 5 indexed citations

17.

Wang, Jiayu, Binghe Xu, Peng Yuan, et al.. (2015). Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer. Medicine. 94(26). e1006–e1006. 9 indexed citations

18.

Wang, Jiayu, Binghe Xu, Peng Yuan, et al.. (2014). HER2 as a Predictive Factor for Successful Neoadjuvant Anthracycline Chemotherapy of Locally Advanced and Early Breast Cancer. The International Journal of Biological Markers. 29(3). 187–192. 7 indexed citations

19.

Fan, Ying, Fei Ma, Qing Li, et al.. (2012). Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis. The Breast. 21(4). 544–549. 16 indexed citations

20.

Wang, Jiayu, Binghe Xu, Peng Yuan, et al.. (2012). TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Breast Cancer Research and Treatment. 135(2). 531–537. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact